Macrophage-Based Therapies for Atherosclerosis Management
Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/8131754 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566079174475776 |
|---|---|
| author | Renyi Peng Hao Ji Libo Jin Sue Lin Yijiang Huang Ke Xu Qinsi Yang Da Sun Wei Wu |
| author_facet | Renyi Peng Hao Ji Libo Jin Sue Lin Yijiang Huang Ke Xu Qinsi Yang Da Sun Wei Wu |
| author_sort | Renyi Peng |
| collection | DOAJ |
| description | Atherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation. |
| format | Article |
| id | doaj-art-80ae946d5bb249b4ae88e0c093b71445 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-80ae946d5bb249b4ae88e0c093b714452025-02-03T01:05:16ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/81317548131754Macrophage-Based Therapies for Atherosclerosis ManagementRenyi Peng0Hao Ji1Libo Jin2Sue Lin3Yijiang Huang4Ke Xu5Qinsi Yang6Da Sun7Wei Wu8Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaInstitute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaInstitute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaInstitute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaDepartment of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaInstitute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, ChinaInstitute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaInstitute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, ChinaAtherosclerosis (AS), a typical chronic inflammatory vascular disease, is the main pathological basis of ischemic cardio/cerebrovascular disease (CVD). Long-term administration was characterized with low efficacy and serious side effects, while the macrophages with attractive intrinsic homing target have great potential in the efficient and safe management of AS. In this review, we focused on the systematical summary of the macrophage-based therapies in AS management, including macrophage autophagy, polarization, targeted delivery, microenvironment-triggered drug release, and macrophage- or macrophage membrane-based drug carrier. In conclusion, macrophage-based therapies have great promise to effectively manage AS in future research and clinic translation.http://dx.doi.org/10.1155/2020/8131754 |
| spellingShingle | Renyi Peng Hao Ji Libo Jin Sue Lin Yijiang Huang Ke Xu Qinsi Yang Da Sun Wei Wu Macrophage-Based Therapies for Atherosclerosis Management Journal of Immunology Research |
| title | Macrophage-Based Therapies for Atherosclerosis Management |
| title_full | Macrophage-Based Therapies for Atherosclerosis Management |
| title_fullStr | Macrophage-Based Therapies for Atherosclerosis Management |
| title_full_unstemmed | Macrophage-Based Therapies for Atherosclerosis Management |
| title_short | Macrophage-Based Therapies for Atherosclerosis Management |
| title_sort | macrophage based therapies for atherosclerosis management |
| url | http://dx.doi.org/10.1155/2020/8131754 |
| work_keys_str_mv | AT renyipeng macrophagebasedtherapiesforatherosclerosismanagement AT haoji macrophagebasedtherapiesforatherosclerosismanagement AT libojin macrophagebasedtherapiesforatherosclerosismanagement AT suelin macrophagebasedtherapiesforatherosclerosismanagement AT yijianghuang macrophagebasedtherapiesforatherosclerosismanagement AT kexu macrophagebasedtherapiesforatherosclerosismanagement AT qinsiyang macrophagebasedtherapiesforatherosclerosismanagement AT dasun macrophagebasedtherapiesforatherosclerosismanagement AT weiwu macrophagebasedtherapiesforatherosclerosismanagement |